In hereditary transthyretin amyloidosis, a misfolded liver protein deposits in nerves and the heart. TTR silencers use RNA interference — a Nobel-winning mechanism — to destroy the messenger RNA for that protein before it is ever made, cutting circulating TTR by around 80%. Patisiran was the first RNAi drug ever approved; vutrisiran does the same job with an injection every three months instead of an infusion every three weeks.
The facts on this page are pulled directly from official U.S. FDA datasets — they are not written from memory. Each field below names the dataset it came from, so you can check it yourself.
Plain-English summaries and drug-class explainers are written and reviewed by the Priya Life Science editorial team, led by Sreepriya Prasannan (MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany). Data is retrieved automatically from the sources above and cross-checked with AI-assisted verification (Anthropic's Claude) — brand and generic names are matched against the exact FDA product record so that a combination product or a different formulation cannot be mistaken for the drug on this page. An editor reviews the result before publication. We describe this in full in our editorial standards and corrections policy. The FDA data on this page was last retrieved on 7 Aug 2026.